Showing 101 to 122 of 122 Results
Page 1 | 2 | 3 | 4 | 5
Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

First Patient Enrolled in Study Evaluating Performance of Spectranetics Laser Ablation Followed by GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
25 February 2008 - Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.

VIBRANT Study of GORE VIABAHN® Endoprosthesis Completes Enrollment
01 January 2008 - Randomized Trial to Assess Patency of Covered Stents vs. Nitinol Stents for the Treatment of Vascular Disease

Endovascular Repair of Descending Thoracic Aortic Aneurysm
26 October 2007 - Heart Disease: On Nov 16th, 2007, see a live endovascular repair of a descending thoracic aortic aneurysm with the GORE TAG® Thoracic Endoprosthesis. Michael D. Dake, MD, Professor of Radiology, Internal Medicine, Surgery and Chairman of the UVA Department of Radiology will host this live broadcast.

Endovascular Repair of Descending Thoracic Aortic Aneurysm
25 October 2007 - On November 6, 2007, at 3 pm (EST) surgeons and radiologists from the University of Michigan Health System will perform a descending thoracic aortic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis.

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Patient Enrollment Begins in Study on Efficacy of GORE SEAMGUARD® Staple Line Reinforcement for Circular Surgical Staplers
21 May 2007 - More than 2,500 colorectal implants of GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement for circular surgical staplers in past year

GORE PRECLUDE® Vessel Guard Reduces Vascular Injury Risk Following Anterior Vertebral Surgery
07 May 2007 - W. L. Gore & Associates (Gore) announced today the availability of GORE PRECLUDE® Vessel Guard, the first non-biological membrane indicated as a cover for vessels following anterior vertebral surgery.

W. L. Gore & Associates enrolls first patient in study of 45 mm GORE TAG® Thoracic Endoprosthesis
20 February 2007 - W. L. Gore & Associates announced today that the first patient has been enrolled in a US Food and Drug Administration (FDA) approved IDE study for the 45 mm* GORE TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta.

Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients - English

Conformable GORE® TAG® Thoracic Endoprosthesis, GORE® EXCLUDER® AAA Endoprosthesis, GORE® EXCLUDER® Iliac Branch Endoprosthesis, GORE® TAG® Thoracic Endoprosthesis

(47 KB, 2 pages, .pdf)


Gore RELINE MAX Study Patient Enrollment Press Release - English

First Patients Enrolled in the Gore RELINE MAX Clinical Study

(45 KB, 3 pages, .pdf)


Showing 101 to 122 of 122 Results
Page 1 | 2 | 3 | 4 | 5